Fecal calprotectin in inflammatory bowel disease

163Citations
Citations of this article
346Readers
Mendeley users who have this article in their library.

Abstract

Inflammatory bowel disease (IBD) and irritable bowel syndrome share many symptoms. While irritable bowel syndrome is a functional bowel disorder for which no specific treatment is available, the range of effective therapies for IBD is evolving rapidly. Accurate diagnosis of IBD is therefore essential. Clinical assessment, together with various imaging modalities and endoscopy, has been the mainstay of diagnosis for many years. Fecal biomarkers of gastrointestinal inflammation have appeared in the past decade, of which calprotectin, a neutrophil cytosolic protein, has been studied the most. Crohn’s disease and ulcerative colitis are chronic remitting and relapsing diseases, and objective assessment of disease activity and response to treatment are important. This review focuses on the use of fecal calprotectin measurements in the diagnosis and monitoring of patients with IBD.

Cite

CITATION STYLE

APA

Walsham, N. E., & Sherwood, R. A. (2016, January 28). Fecal calprotectin in inflammatory bowel disease. Clinical and Experimental Gastroenterology. Dove Medical Press Ltd. https://doi.org/10.2147/CEG.S51902

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free